Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012

VIEWS: 30 PAGES: 143

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2012, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) therapeutic pipeline. This report provides information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye). 'Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
  • pg 1
									Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review,
                        H1 2012


                                                                                          Reference Code: GMDHC1822IDB
                                                                                             Publication Date: March 2012




Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012                             GMDHC1822IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(1)
Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 8
    List of Figures ................................................................................................................................................................................ 9
Introduction....................................................................................................................................................................................... 10
    Global Markets Direct Report Coverage ...................................................................................................................................... 10
Keratoconjunctivitis sicca (Dry Eye) Overview ................................................................................................................................. 11
Therapeutics Development............................................................................................................................................................... 12
    An Overview of Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) ................................................................................. 12
Keratoconjunctivitis sicca (Dry Eye) Therapeutics under Development by Companies .................................................................... 14
Keratoconjunctivitis sicca (Dry Eye) Therapeutics under Investigation by Universities/Institutes ..................................................... 18
Late Stage Products ......................................................................................................................................................................... 19
    Comparative Analysis .................................................................................................................................................................. 19
Mid Clinical Stage Products.............................................................................................................................................................. 20
    Comparative Analysis .................................................................................................................................................................. 20
Early Clinical Stage Products ........................................................................................................................................................... 21
    Comparative Analysis .................................................................................................................................................................. 21
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 22
    Comparative Analysis .................................................................................................................................................................. 22
Keratoconjunctivitis sicca (Dry Eye) Therapeutics – Products under Development by Companies.................................................. 23
Keratoconjunctivitis sicca (Dry Eye) Therapeutics – Products under Investigation by Universities/Institutes ................................... 26
Companies Involved in Keratoconjunctivitis sicca (Dry Eye) Therapeutics Development ................................................................ 27
    Alcon, Inc. .................................................................................................................................................................................... 27
    Allergan, Inc................................................................................................................................................................................. 28
    Bayer HealthCare AG .................................................................................................................................................................. 29
    Merck & Co., Inc. ......................................................................................................................................................................... 30
    Santen Pharmaceutical Co., Ltd. ................................................................................................................................................. 31
    arGentis Pharmaceuticals, LLC ................................................................................................................................................... 32
    Sylentis ........................................................................................................................................................................................ 33
    Novagali Pharma SA ................................................................................................................................................................... 34
    Dong-A Pharmaceutical Co., Ltd. ................................................................................................................................................ 35
    Kissei Pharmaceutical Co., Ltd. ................................................................................................................................................... 36
    Pfizer Inc...................................................................................................................................................................................... 37
    ISTA Pharmaceuticals, Inc. ......................................................................................................................................................... 38
    InSite Vision Incorporated ........................................................................................................................................................... 39
    iCo Therapeutics Inc.................................................................................................................................................................... 40
    Can-Fite BioPharma Ltd. ............................................................................................................................................................. 41
    NovaBay Pharmaceuticals, Inc. ................................................................................................................................................... 42
    RegeneRx Biopharmaceuticals, Inc............................................................................................................................................. 43
    Sirion Therapeutics, Inc. .............................................................................................................................................................. 44
    R-Tech Ueno, Ltd. ....................................................................................................................................................................... 45
    SCYNEXIS, Inc............................................................................................................................................................................ 46
    Parion Sciences, Inc. ................................................................................................................................................................... 47



Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012                                                                                  GMDHC1822IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                    Page(2)
Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012




    SARcode Corporation.................................................................................................................................................................. 48
    Resolvyx Pharmaceuticals, Inc .................................................................................................................................................... 49
    Morria Biopharmaceuticals Plc .................................................................................................................................................... 50
    SIFI Pharma ................................................................................................................................................................................ 51
    DSM Nutritional Products AG ...................................................................................................................................................... 52
    Altacor Ltd. .................................................................................................................................................................................. 53
    Mimetogen Pharmaceuticals Inc.................................................................................................................................................. 54
Keratoconjunctivitis sicca (Dry Eye) – Therapeutics Assessment .................................................................................................... 55
    Assessment by Monotherapy Products ....................................................................................................................................... 55
    Assessment by Route of Administration ...................................................................................................................................... 56
    Assessment by Molecule Type .................................................................................................................................................... 58
Drug Profiles..................................................................................................................................................................................... 60
    Prolacria - Drug Profile ................................................................................................................................................................ 60
        Product Description................................................................................................................................................................. 60
        Mechanism of Action ............................................................................................................................................................... 60
        R&D Progress ......................................................................................................................................................................... 60
    Prolacria - Drug Profile ................................................................................................................................................................ 62
        Product Description................................................................................................................................................................. 62
        Mechanism of Action ............................................................................................................................................................... 62
        R&D Progress ......................................................................................................................................................................... 62
    Tofacitinib - Drug Profile .............................................................................................................................................................. 64
        Product Description................................................................................................................................................................. 64
        Mechanism of Action ............................................................................................................................................................... 64
        R&D Progress ......................................................................................................................................................................... 64
    Ecabet - Drug Profile ................................................................................................................................................................... 66
        Product Description................................................................................................................................................................. 66
        Mechanism of Action ............................................................................................................................................................... 66
        R&D Progress ......................................................................................................................................................................... 66
    AIN457 - Drug Profile .................................................................................................................................................................. 67
        Product Description................................................................................................................................................................. 67
        Mechanism of Action ............................................................................................................................................................... 67
        R&D Progress ......................................................................................................................................................................... 67
    ARG103 - Drug Profile ................................................................................................................................................................. 69
        Product Description................................................................................................................................................................. 69
        Mechanism of Action ............................................................................................................................................................... 69
        R&D Progress ......................................................................................................................................................................... 69
    Xerophthalmia Program - Drug Profile ........................................................................................................................................ 70
        Product Description................................................................................................................................................................. 70
        Mechanism of Action ............................................................................................................................................................... 70
        R&D Progress ......................................................................................................................................................................... 70
    ARG101 - Drug Profile ................................................................................................................................................................. 71
        Product Description................................................................................................................................................................. 71
        Mechanism of Action ............................................................................................................................................................... 71
        R&D Progress ......................................................................................................................................................................... 71


Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012                                                                                GMDHC1822IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012




    ARG102 - Drug Profile ................................................................................................................................................................. 72
        Product Description................................................................................................................................................................. 72
        Mechanism of Action ............................................................................................................................................................... 72
        R&D Progress ......................................................................................................................................................................... 72
    CF101 - Drug Profile.................................................................................................................................................................... 73
        Product Description................................................................................................................................................................. 73
        Mechanism of Action ............................................................................................................................................................... 73
        R&D Progress ......................................................................................................................................................................... 73
    RGN-259 - Drug Profile ............................................................................................................................................................... 75
        Product Description................................................................................................................................................................. 75
        Mechanism of Action ............................................................................................................................................................... 75
        R&D Progress ......................................................................................................................................................................... 75
    OPC-12759E - Drug Profile ......................................................................................................................................................... 77
        Product Description................................................................................................................................................................. 77
        Mechanism of Action ............................................................................................................................................................... 77
        R&D Progress ......................................................................................................................................................................... 77
    Cyclosporine - Drug Profile .......................................................................................................................................................... 79
        Product Description................................................................................................................................................................. 79
        Mechanism of Action ............................................................................................................................................................... 79
        R&D Progress ......................................................................................................................................................................... 79
    Remura - Drug Profile .................................................................................................................................................................. 80
        Product Description................................................................................................................................................................. 80
        Mechanism of Action ............................................................................................................................................................... 80
        R&D Progress ......................................................................................................................................................................... 80
    SAR1118 - Drug Profile ............................................................................................................................................................... 81
        Product Description................................................................................................................................................................. 81
        Mechanism of Action ............................................................................................................................................................... 81
        R&D Progress ......................................................................................................................................................................... 81
    AL 43546 - Drug Profile ............................................................................................................................................................... 83
        Product Description................................................................................................................................................................. 83
        Mechanism of Action ............................................................................................................................................................... 83
        R&D Progress ......................................................................................................................................................................... 83
    Cyclokat - Drug Profile ................................................................................................................................................................. 84
        Product Description................................................................................................................................................................. 84
        Mechanism of Action ............................................................................................................................................................... 84
        R&D Progress ......................................................................................................................................................................... 84
    RX-10001 - Drug Profile .............................................................................................................................................................. 86
        Product Description................................................................................................................................................................. 86
        Mechanism of Action ............................................................................................................................................................... 86
        R&D Progress ......................................................................................................................................................................... 86
    ProtoCure - Drug Profile .............................................................................................................................................................. 88
        Product Description................................................................................................................................................................. 88
        Mechanism of Action ............................................................................................................................................................... 88
        R&D Progress ......................................................................................................................................................................... 88


Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012                                                                             GMDHC1822IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(4)
Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H1 2012




    iCo-008 - Drug Profile .................................................................................................................................................................. 89
        Product Description................................................................................................................................................................. 89
        Mechanism of Action ............................................................................................................................................................... 89
        R&D Progress ......................................................................................................................................................................... 89
    Mapracorat - Drug Profile ............................................................................................................................................................ 91
        Product Description................................................................................................................................................................. 91
        Mechanism of Action ............................................................................................................................................................... 91
        R&D Progress ......................................................................................................................................................................... 91
    RX-20001 - Drug Profile .............................................................................................................................................................. 93
        Product Description................................................................................................................................................................. 93
        Mechanism of Action ............................................................................................................................................................... 93
        R&D Progress ......................................................................................................................................................................... 93
    RU-101 - Drug Profile .................................................................................................................................................................. 94
        Product Descriptio
								
To top